Congressional Research Service Issues In Focus White Paper on Medicare Coverage of GLP-1 Drugs
September 10, 2024
September 10, 2024
WASHINGTON, Sept. 10 -- The Congressional Research Service issued the following In Focus white paper (No. IF12758) on Sept. 9, 2024, by Health Care Financing analyst Laura A. Wreschnig.
Here are excerpts:
* * *
Medicare Coverage of GLP-1 Drugs
Glucagon-like peptide-1 (GLP-1) receptor agonists, marketed under brand names such as Wegovy and Ozempic, are a class of medications used primarily in the treatment of type 2 diabetes mellitus (T2DM). Rec . . .
Here are excerpts:
* * *
Medicare Coverage of GLP-1 Drugs
Glucagon-like peptide-1 (GLP-1) receptor agonists, marketed under brand names such as Wegovy and Ozempic, are a class of medications used primarily in the treatment of type 2 diabetes mellitus (T2DM). Rec . . .